Charles River Laboratories Receives Consensus Recommendation of “Hold” from Analysts (NYSE:CRL)
Shares of Charles River Laboratories (NYSE:CRL) have been given an average recommendation of “Hold” by the fourteen ratings firms that are presently covering the company, Stock Ratings Network reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $54.15.
Shares of Charles River Laboratories (NYSE:CRL) opened at 57.52 on Friday. Charles River Laboratories has a one year low of $40.28 and a one year high of $62.50. The stock has a 50-day moving average of $59.12 and a 200-day moving average of $54.86. The company has a market cap of $2.741 billion and a P/E ratio of 27.08.
Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $289.20 million for the quarter, compared to the consensus estimate of $289.56 million. During the same quarter in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, analysts predict that Charles River Laboratories will post $3.17 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on CRL shares. Analysts at Jefferies Group raised their price target on shares of Charles River Laboratories to $73.00 in a research note on Thursday, April 10th. They now have a “buy” rating on the stock. Separately, analysts at KeyCorp initiated coverage on shares of Charles River Laboratories in a research note on Wednesday, March 19th. They set a “hold” rating on the stock. Finally, analysts at Ned Davis Research upgraded shares of Charles River Laboratories from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 18th.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.